EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening.

ABSTRACT:

Background

New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico screens that cannot predict their in vivo effect.

Methods

We screened an Adeno-Associated Vector secretome library (> 1000 clones) directly in vivo in a mouse model of cancer and validated the therapeutic effect of the first hit, EMID2, in both orthotopic and genetic models of lung and pancreatic cancer.

Results

EMID2 overexpression inhibited both tumor growth and metastatic dissemination, consistent with prolonged survival of patients with high levels of EMID2 expression in the most aggressive human cancers. Mechanistically, EMID2 inhibited TGFβ maturatio

SUBMITTER: Cappelletto A 

PROVIDER: S-EPMC10777502 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature